CovidChloroV1, Main, Exploration, bibRecord, 000C09

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.

Identifieur interne : 000C09 ( Main/Exploration ); précédent : 000C08; suivant : 000C10

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.

Auteurs : Kome Gbinigie [Royaume-Uni] ; Kerstin Frie [Royaume-Uni]

Source :

BJGP open [ 2398-3795 ] ; 2020.

RBID : pubmed:32265182

Abstract

BACKGROUND

On the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this, there has been growing interest in the use of existing medications, such as chloroquine (CQ) and hydroxychloroquine (HCQ), as potential treatments of this disease.

AIM

To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19.

DESIGN & SETTING

A rapid review of the literature was conducted.

METHOD

Electronic searches in PubMed and Google Scholar were conducted on 21 March 2020. A further search was conducted in Google for relevant literature on 28 March 2020.

RESULTS

There is limited evidence of in vitro activity of CQ/HCQ against SARS-CoV-2. A number of in vivo clinical trials are underway. The empirical data available from two of these trials reveal conflicting results. Both trials are characterised by small numbers of participants (

CONCLUSION

At present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19. High quality, adequately powered randomised clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium- and long-term follow-up results, and safety data.

DOI: 10.3399/bjgpopen20X101069
PubMed: 32265182
PubMed Central: PMC7330219

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001A16
to stream Main, to step Curation: 001A16

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.</title>
<author><name sortKey="Gbinigie, Kome" sort="Gbinigie, Kome" uniqKey="Gbinigie K" first="Kome" last="Gbinigie">Kome Gbinigie</name>
<affiliation wicri:level="4"><nlm:affiliation>GP and Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK Oghenekome.gbinigie@phc.ox.ac.uk.</nlm:affiliation>
<country wicri:rule="url">Royaume-Uni</country>
<wicri:regionArea>GP and Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Frie, Kerstin" sort="Frie, Kerstin" uniqKey="Frie K" first="Kerstin" last="Frie">Kerstin Frie</name>
<affiliation wicri:level="4"><nlm:affiliation>Post-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Post-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32265182</idno>
<idno type="pmid">32265182</idno>
<idno type="doi">10.3399/bjgpopen20X101069</idno>
<idno type="pmc">PMC7330219</idno>
<idno type="wicri:Area/Main/Corpus">001A16</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A16</idno>
<idno type="wicri:Area/Main/Curation">001A16</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001A16</idno>
<idno type="wicri:Area/Main/Exploration">001A16</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.</title>
<author><name sortKey="Gbinigie, Kome" sort="Gbinigie, Kome" uniqKey="Gbinigie K" first="Kome" last="Gbinigie">Kome Gbinigie</name>
<affiliation wicri:level="4"><nlm:affiliation>GP and Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK Oghenekome.gbinigie@phc.ox.ac.uk.</nlm:affiliation>
<country wicri:rule="url">Royaume-Uni</country>
<wicri:regionArea>GP and Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Frie, Kerstin" sort="Frie, Kerstin" uniqKey="Frie K" first="Kerstin" last="Frie">Kerstin Frie</name>
<affiliation wicri:level="4"><nlm:affiliation>Post-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Post-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">BJGP open</title>
<idno type="eISSN">2398-3795</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>On the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this, there has been growing interest in the use of existing medications, such as chloroquine (CQ) and hydroxychloroquine (HCQ), as potential treatments of this disease.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>AIM</b>
</p>
<p>To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>DESIGN & SETTING</b>
</p>
<p>A rapid review of the literature was conducted.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHOD</b>
</p>
<p>Electronic searches in PubMed and Google Scholar were conducted on 21 March 2020. A further search was conducted in Google for relevant literature on 28 March 2020.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>There is limited evidence of in vitro activity of CQ/HCQ against SARS-CoV-2. A number of in vivo clinical trials are underway. The empirical data available from two of these trials reveal conflicting results. Both trials are characterised by small numbers of participants (</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>At present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19. High quality, adequately powered randomised clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium- and long-term follow-up results, and safety data.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32265182</PMID>
<DateRevised><Year>2021</Year>
<Month>02</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2398-3795</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>4</Volume>
<Issue>2</Issue>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>BJGP open</Title>
<ISOAbbreviation>BJGP Open</ISOAbbreviation>
</Journal>
<ArticleTitle>Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">bjgpopen20X101069</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.3399/bjgpopen20X101069</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">On the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this, there has been growing interest in the use of existing medications, such as chloroquine (CQ) and hydroxychloroquine (HCQ), as potential treatments of this disease.</AbstractText>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19.</AbstractText>
<AbstractText Label="DESIGN & SETTING" NlmCategory="METHODS">A rapid review of the literature was conducted.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">Electronic searches in PubMed and Google Scholar were conducted on 21 March 2020. A further search was conducted in Google for relevant literature on 28 March 2020.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">There is limited evidence of in vitro activity of CQ/HCQ against SARS-CoV-2. A number of in vivo clinical trials are underway. The empirical data available from two of these trials reveal conflicting results. Both trials are characterised by small numbers of participants (<i>n</i>
 = 30 and <i>n</i>
 = 36) and suffer methodological limitations. No medium or long-term follow-up data is available.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">At present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19. High quality, adequately powered randomised clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium- and long-term follow-up results, and safety data.</AbstractText>
<CopyrightInformation>Copyright © 2020, The Authors.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gbinigie</LastName>
<ForeName>Kome</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>GP and Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK Oghenekome.gbinigie@phc.ox.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Frie</LastName>
<ForeName>Kerstin</ForeName>
<Initials>K</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-4717-5874</Identifier>
<AffiliationInfo><Affiliation>Post-Doctoral Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>205212/Z/16/Z</GrantID>
<Acronym>WT_</Acronym>
<Agency>Wellcome Trust</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BJGP Open</MedlineTA>
<NlmUniqueID>101713531</NlmUniqueID>
<ISSNLinking>2398-3795</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Chloroquine</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">coronavirus</Keyword>
<Keyword MajorTopicYN="N">general practice</Keyword>
<Keyword MajorTopicYN="N">primary healthcare</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32265182</ArticleId>
<ArticleId IdType="pii">bjgpopen20X101069</ArticleId>
<ArticleId IdType="doi">10.3399/bjgpopen20X101069</ArticleId>
<ArticleId IdType="pmc">PMC7330219</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Drug Discov Ther. 2020;14(1):58-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32147628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Ophthalmol. 2002 May;133(5):649-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11992862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105945</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Dis Rep. 2020 Mar 16;12(1):8543</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32218915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 20;43(0):E019</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32075365</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2007 May;46(5):808-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17202178</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 1996 Mar;55(3):187-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8712882</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br Heart J. 1993 May;69(5):451-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8518071</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Acad Emerg Med. 2020 Mar 9;8(1):e17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32185369</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Perspect Clin Res. 2016 Jul-Sep;7(3):144-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27453832</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurosurg Focus. 2015 Mar;38(3):E12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25727221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab Syndr. 2020 May - Jun;14(3):241-246</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32247211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):62-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8278820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>World J Pediatr. 2020 Jun;16(3):271-274</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32166483</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>R Soc Open Sci. 2017 Feb 1;4(2):160254</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28386409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar;55(3):105923</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32070753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2020 Jun;57:279-283</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jun 4;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32497323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 2017 Mar;44(3):398</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28250164</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>HIV Med. 2015 Nov;16(10):585-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26238012</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Oxfordshire</li>
</region>
<settlement><li>Oxford</li>
</settlement>
<orgName><li>Université d'Oxford</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Gbinigie, Kome" sort="Gbinigie, Kome" uniqKey="Gbinigie K" first="Kome" last="Gbinigie">Kome Gbinigie</name>
</region>
<name sortKey="Frie, Kerstin" sort="Frie, Kerstin" uniqKey="Frie K" first="Kerstin" last="Frie">Kerstin Frie</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C09 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C09 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32265182
   |texte=   Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32265182" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki